Original Article from The New England Journal of Medicine — Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
POLARIX was published in NEJM the same day as the late breaking abstract presentation at ASH. There has been much discussion online about cost and subgroups which may have the greatest benefit. See the supplemental materials in the article for the subgroup analysis. While there seems to be much enthusiasm about increased signal of benefit among highest IPI groups, remember, these were not pre-planed and several of the subgroups with benefit do not have biologic plausibility.